Polymorphisms of the Pfatpase 6 and Pfcrt gene and their relationship with the in vitro susceptibility to dihydroartemisinin and chloroquine of Plasmodium falciparum isolates from Abobo, Cote d’Ivoire

• Autorzy: Bla B.K. , Yavo W. , Trebissou J. , Kipre R. G. , Yapi F. H. , N'guessan J. D. , Djaman J. A.
• Języki publikacji: EN

Abstrakty

EN

As a result of widespread resistance to chloroquine (CQ) and sulphadoxine-pyrimethamine (SP), artemisinin-based combination therapy (ACT) has been recommended as a first-line anti-malarial regimen in Côte d’Ivoire since 2005. A thorough understanding of the molecular bases of P. falciparum resistance to existing drugs is therefore needed. The aims of this study were to analyze the in vitro sensitivity of P. falciparum field isolates from Abobo to CQ, pyronaridine (PYR) and dihydroartemisinine (DHA), and to investigate the polymorphisms associated with drug resistance. The standard in vitro drug sensitivity microtechnique recommended by the WHO was used to assess the sensitivity of Plasmodium falciparum isolates collected in December 2006. The Pfcrt haplotype 76 was analysed by PCR-RFLP while Pfatpase 6 amplification products were sequenced. Associations between drug sensitivity and parasite gene polymorphisms were evaluated with Cohen’s kappa test. The correlation between the IC50 values for different drugs was assessed by the coefficient of determination (r2). Significance was assumed at p<0.05. Of 128 in vitro tests performed, 112 (87.5%) were successful. Of the isolates, 56.2% were resistant for CQ and 48% for PYR. One isolate (3.6%) demonstrated reduced DHA sensitivity (IC50 higher than 10 nM). The mutant K76T pfcrt codon, present in 90% of DNA fragments analyzed, was associated with CQ-R (ĸ=0.76). The N669Y (16.1%), D734Y (28.6%) and D734H (1.8%) isolates were found to have mutant Pfatpase6, however, these mutations were not associated with diminished DHA sensitivity (k=0.01). These high levels of antimalarial drug resistance in Abobo (Côte d’Ivoire) demand further studies of drug efficacy across the whole country.

Słowa kluczowe

EN

polymorphism; Pfatpase 6; Pfcrt gene; relationship; in vitro; susceptibility; dihydroartemisinin; malaria; chloroquine; Plasmodium falciparum; isolate; drug resistance; Abobo commune; Cote d’Ivoire

• Wydawca: -
• Czasopismo: Annals of Parasitology
• Rocznik: 2014
• Tom: 60
• Numer: 4
• Opis fizyczny: p.259-266,fig.,ref.

Twórcy

autor

Bla B.K.

• Department of Biochemistry, UFR of Biosciences, University of Felix Houphouet Boigny, 22 BP 582, Abidjan 22, Cote d’Ivoire

autor

Yavo W.

• Department of Parasitology, UFR of Pharmaceutical and Biology Sciences, University of Felix Houphouet Boigny, 01 BP V34 Abidjan 01, Cote d’Ivoire

autor

Trebissou J.

• Department of Biochemistry, UFR of Biosciences, University of Felix Houphouet Boigny, 22 BP 582, Abidjan 22, Cote d’Ivoire

autor

Kipre R. G.

• Department of Biochemistry, UFR of Biosciences, University of Felix Houphouet Boigny, 22 BP 582, Abidjan 22, Cote d’Ivoire

autor

Yapi F. H.

• Department of Biochemistry, UFR of Biosciences, University of Felix Houphouet Boigny, 22 BP 582, Abidjan 22, Cote d’Ivoire

autor

N'guessan J. D.

• Department of Biochemistry, UFR of Biosciences, University of Felix Houphouet Boigny, 22 BP 582, Abidjan 22, Cote d’Ivoire

autor

Djaman J. A.

• Department of Biochemistry, UFR of Biosciences, University of Felix Houphouet Boigny, 22 BP 582, Abidjan 22, Cote d’Ivoire
• Department of Clinical and Fundamental Biochemistry, Institute Pasteur of Cote d’Ivoire, 01 BP 490 Abidjan 01, Cote d’Ivoire

Bibliografia

• [1] WHO: World Malaria Report 2010. Geneva: World Health Organization 2010: 32.
• [2] Assoumou, A., Adoubryn K.D., Aboum K.S., Kouadio-Yapo C.G., Ouhon J. 2008. Symptomatic and asymptomatic Plasmodium falciparum infection in children from 6 months to 6 years old in the Abobo general hospital (Abidjan, Côte d’Ivoire). Bulletion de la Société de Pathologie Exotique 101: 50-53.
• [3] Djaman A.J., Basco L.K., Mazabraud A. 2002. Surveillance de la chimiorésistance de Plasmodium falciparum à Yopougon (Abidjan): étude in vivo de la sensibilité à la chloroquine et évaluation de la résistance à la pyriméthamine suivie de l’analyse du point de mutation du gène de la dihydrofolate réductase. Santé 12: 363-367.
• [4] Djaman A.J., Bla B.K., Yavo W., Yapi H.F., Mazabraud A., Basco L.K. 2007. Polymorphism of PFCRT and PFMDR-1 Genes of Plasmodium falciparum and Chloroquine susceptibility in Côte d’Ivoire. Acta Protozoologica 46: 361-365.
• [5] Djaman A.J., Ahibo H., Yapi F.H., Bla B.K., Ouattara L., Yavo W., N’guessan J.D., Yapo A., Mazabraud A. 2010. Molecular monitoring of P. falciparaum malaria isolates in Côte d’Ivoire: genetic markers (dhfr-ts, dhps, pfcrt, pfmdr-1) for antimalarial-drugs resistance. European Journal of Scientific Research 40: 461-470.
• [6] Sidhu A.B., Verdier-Pinard D., Fidock D.A. 2002. Chloroquine resistance in P. falciparum malaria parasites conferred by pfcrt mutations. Science 298: 210-213.
• [7] Djimdé A., Doumbo O.K., Cortese J.F., Kayentao K., Doumbo S., Diourté Y., Dicko A., Su X.Z., Nomura T., Fidock D.A., Wellems T.E., Plowe C.V., Coulibaly D. 2001. A molecular marker for chloroquine resistant falciparum. The New England Journal of Medicine 344: 257-263.
• [8] Tinto H., Ouédraogo J.B., Erhart A., Van Overmeir C., Dujardin J.C., Van Marck E., Guiguemdé T.R., D’Alessandro U. 2003. Relationship between the Pfcrt T76 and the Pfmdr-1 Y86 mutations in Plasmodium falciparum and in vitro/in vivo chloroquine resistance in Burkina Faso, West Africa. Infection, Genetics and Evolution 3: 287-292.
• [9] Hyde J.E. 2002. Mechanisms of resistance of Plasmodium falciparum to antimalarial drugs. Microbes and Infection 4: 165-174.
• [10] Kublin J.G., Dzinjalamala F.K., Kamwendo D.D., Malkin E.M., Cortese J.F., Martino L.M., Mukadam R.A., Rogerson S.J., Lescano A.G., Molyneux M.E., Winstanley P.A., Chimpeni P., Taylor T.E., Plowe C.V. 2002. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanildapsone treatment of Plasmodium falciparum malaria. The Journal of Infectious Diseases 185: 380-388.
• [11] Triglia T., Wang P., Sims P., Hyde J., Cowman A.F. 1998. Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthetase in sulfadoxine-resistant malaria. The EMBO Journal 17: 3807-3815.
• [12] White N.J. 2001. Preventing antimalarial drug resistance through combinations. Drug Resistance Updates 1: 3-9.
• [13] World Health Organization: In vitro micro-test (Mark III) for the assessment of the response of Plasmodium falciparum to chloroquine, mefloquine, quinine, amodiaquine, sulfadoxine/pyrimethamine and artemisinin: Instructions for use of the in vitro micro-test kit (Mark III) CTD/MAL/97.20. [http://whqlibdoc.who. int/hq/2001/a76873.pdf].
• [14] Mazoyer B., Mary J.Y. 1987. Le kappa utilisé comme mesure de reproductibilité: distribution sous l’hypothèse nulle. Revue d’Èpidémiologie et de Santé Publique 35: 474-481.
• [15] Bray P.G., Mungthin M., Ridley R.G., Ward S.A. 1998. Access to hematin: the basis of chloroquine resistance. Molecular Pharmacology 54: 170-179.
• [16] Ridley R.G. 1998. Malaria: dissecting chloroquine resistance. Current Biology 8: R346-R349.
• [17] Price R.N., Uhlemann A.C., Brockman A., Mcgready R., Ashley E., Phaipun L., Patel R., Laing K., Looareesuwan S., White N.J., Nosten F., Krishna S. 2004. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 364: 438-447.
• [18] Jambou R., Legrand E., Niang M., Khim N., Lim P ., Volney B., Ekala M.T., Bouchier C., Esterre P., Fandeur T., Mercereau-Puijalon O. 2005. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 366: 1960-1963.
• [19] Mugittu K., Genton B., Mshinda H., Beck H.P. 2006. Molecular monitoring of Plasmodium falciparum resistance to artemisinin in Tanzania. Malaria Journal 5:126.
• [20] Zhang G., Guan Y., Zheng B., Wu S. Tang L. 2008. No PfATPase6 S769N mutation found in Plasmodium falciparum isolates from China. Malaria Journal 7: 122.
• [21] Bennett T.N., Patel J., Ferdig M.T. Roepe P.D. 2007. P. falciparum Na(+)/H(+) exchanger activity and quinine resistance. Molecular and Biochemical Parasitology 153: 48-58.
• [22] Mercereau-Puijalon O., Fandeur T. 2003. Antimalarial activity of artemisinins: identification of a novel target? Lancet 362: 2035-2036.
• [23] Eckstein-Ludwig U., Webb R.J., Van Goethem I.D., East J.M., Lee A.G., Kimura M., O’Neill P.M., Bray P.G., Ward S.A. Krishna S. 2003. Artemisinins target the SERCA of Plasmodium falciparum. Nature 424: 957-961.
• [24] Menegon M., Sannella A.R., Majori G. Severini C. 2008. Detection of novel point mutations in the Plasmodium falciparum ATPase6 candidate gene for resistance to artemisinins. Parasitology International 57: 233-235.